Stevanato Group (STVN) is discussed as a compounder benefiting from the GLP-1 boom, but faces uncertainty regarding oral GLP-1s and its significant capex investments.
Source Post
$STVN: are oral GLP-1s really a death blow? | Aurelian Research's Leo Trudel
May 5, 2026
The podcast discusses Stevanato Group (STVN), a manufacturer of containers for biologics and drugs, and its position in the GLP-1 market. The discussion touches on the company's capital expenditures, the potential impact of oral GLP-1s, and its valuation. The episode also features a sponsor segment for AlphaSense, highlighting its AI tools for earnings season analysis.
Linked Mentions
Tickers discussed in this post
Linked Signals
Tracked calls opened from this post
No linked signals were opened directly from this post.